Seer Files ITC Complaint Against Nanomics, Seeks Import Ban on Infringing Proteonano Products
SEER is trading near its 52-week low of $1.65 (13% above the low) on light trading volume (0.3× avg).
Summary
Seer has filed a complaint with the International Trade Commission (ITC) against Nanomics Biotechnology, alleging patent infringement related to its nanoparticle protein enrichment technology. Brigham and Women's Hospital has joined the complaint. This action, which follows a federal district court suit filed on May 12, seeks an exclusion order to block Nanomics' Proteonano kits and workstations from entering the U.S. This is a significant move to protect Seer's intellectual property and competitive position in its core market.
At the time of this announcement, SEER was trading at $1.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $106.1M. The 52-week trading range was $1.65 to $2.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.